Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis

Jenkins, Paul J.; Khalaf, Sahira; Ogunkolade, W; McCarthy, Kathryn; Tomaz, David; Hands, Rebecca; Davies, Derek; Bustin, Stephen A.

doi:10.1677/erc.1.01080

Cited by 27 publications

(26 citation statements)

References 23 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the expression of IGF-1 mRNA evaluated by Jenkins et al was lower in CRC than in control samples (2.6x10 5 vs. 4.7x10 5 copy number/µg total RNA, respectively), which was similar to our results (47).…”

Section: Discussionsupporting

confidence: 92%

“…In this study, the expression of total mRNA and all splicing isoforms of IGF-1 mRNA was observed in all the examined CRC and control samples. Existing data on the detection of IGF-1 mRNA vary between the absence of the transcript in CRC tissue (46), HT-29 and CaCo-2 cells (47), its detection in a proportion of cases (41-54% in CRC and 60-67% in control samples) (47)(48)(49) to its demonstration in all (100%) CRC and normal colon samples (50), which was supported by our results.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue

et al. 2012

View full text Add to dashboard Cite

Abstract. The insulin-like growth factor (IGF)-1 gene consists of 6 exons resulting in the expression of 6 variant forms of mRNA (IA, IB, IC, IIA, IIB and IIC) due to an alternative splicing. The mechanisms of IGF-1 gene splicing and the role of local expression manifested by IGF-1 mRNA variants in colorectal carcinoma (CRC) have not been extensively investigated. Therefore, the aim of our study was to analyse the expression of IGF-1 mRNA isoforms [A, B, C, P1 (class I) and P2 (class II)], as well as the protein expression in CRC and control samples isolated from 28 patients. The expression of Ki-67 was also analysed and clinical data were obtained. For this purpose, we used quantitative real-time PCR (qPCR) and immunocytochemistry. The expression of mRNAs coding for all splicing isoforms of IGF-1 was observed in every tissue sample studied, with a significantly lower expression noted in the CRC as compared to the control samples. The cytoplasmic expression of IGF-1 protein was found in 50% of the CRC and in ~40% of the non-tumor tissues; however, no significant quantitative inter-group differences were observed. The expression of the IGF-1 gene in the 2 groups of tissues was controlled by the P1 and P2 promoters in a similar manner. No significant differences were detected in the expression of the IGF-1 A and B isoforms; however, their expression was significantly higher compared to that of isoform C. No significant differences were observed between the expression of Ki-67 mRNA in the CRC and control tissue even though the expression of the Ki-67 protein was higher in the CRC compared to the control samples. Ki-67 protein expression was associated with the macroscopic and microscopic aspects of CRC. A significant positive correlation was found between the local production of total mRNA and isoform A and the expression of Ki-67 mRNA, although only in the non-tumor tissues. In CRC samples, the local expression of the total IGF-1 mRNA and all splicing isoforms of IGF-1 mRNA decreased as compared to the normal colon tissues, although however, with conservation of both gene promoter activities and with the continued principal splicing IGF-1 mRNA isoforms.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 89%

Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In addition, differential antiproliferative effects of IGFBP-3 on colon cancer cells have been demonstrated. Treatment with IGFBP-3 for 24 h resulted in a significant decrease in proliferation of CaCo-2 cells, while there was no effect on HT29 cells [28]. Moreover, our results showed that, using high doses of rhIGFBP-3, a decrease of antiproliferative effects, although marginal, was observed which reflects the ability of rhIGFBP-3 to promote cell growth.…”

Section: Discussionmentioning

confidence: 49%

“…1 We have initially tested several time points 24, 48, 72 and 96 h, as previously reported [28,24,29]. While there were no obvious effects of rhIGFBP-3 following 24 and 48 h incubation (data not shown), similar growth inhibitory effects were observed at 72 and 96 h time points.…”

Section: Rhigfbp-3 Inhibits the Tumor Growth In The M-3ll Cells In VImentioning

confidence: 65%

Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models

Alami

Pagé

et al. 2008

Growth Hormone & IGF Research

View full text Add to dashboard Cite

“…On the contrary, undifferentiated colorectal cancer shows weak staining for IGFBP-3 (Williams et al 2000). In fact, it seems that only the stromal component of the tumors, but not the malignant epithelial cells, expresses IGFBP-3 as a feedback mechanism of IGF-IR regulation (Jenkins et al 2005). This could be related either to an aberrant promoter methylation of IGFBP-3 (Tomii et al 2007) or to the mutational status of p53 (Buckbinder et al 1995).…”

Section: Introductionmentioning

confidence: 99%

Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer

Gallego¹,

Codony-Servat²,

García-Albéniz³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

Insulin-like growth factor-I (IGF-I) is thought to have antiapoptotic and mitogenic properties in colorectal cancer, whereas IGF-binding protein-3 (IGFBP-3) seems to exert a pro-apoptotic effect. Additionally, matrix metalloproteinase-7 (MMP-7), an enzyme with in vitro ability to degrade IGFBP-3, has been shown to be a prognostic factor in advanced colorectal cancer (ACRC). We studied whether chemotherapy treatment for ACRC modulates IGF-I, IGFBP-3, and MMP-7 serum levels. In 41 patients undergoing first-line therapy for ACRC, serum levels of IGF-I, IGFBP-3, and MMP-7 were measured with immunoassays at baseline and every 3 months until progressive disease, or a maximum of five determinations, during a chemotherapy regimen of either FOLFOX or FOLFIRI therapies. Associations were assessed for paired samples, using t-test or Wilcoxon ranks test depending on normality of the variable, verified with Shapiro-Wilk test. An average of four extractions (range 3-5) were done, for a total of 157 determinations. Mean pretreatment values of IGF-I, IGFBP-3, and MMP-7 were 83 (95% CI, 73-92) ng/ml, 2372 (95% CI, 2121-2623) ng/ml, and 10.6 (95% CI, 7.21-13.98) ng/ml respectively. No significant changes in IGF-I were found, but a significant increase in IGFBP-3 serum concentrations was observed during or after chemotherapy treatment without progressive disease, compared with basal levels (P!0.001). A significant decrease in IGFBP-3 to 1983 ng/ml (95% CI, 1675-2292) and a significant increase in MMP-7 levels to 14.6 (7.6-21.7) ng/ml were observed at progression of disease compared with baseline and treatment levels (P!0.001). This study shows that IGFBP-3 and MMP-7 serum levels change during chemotherapy treatment. The increased MMP-7 levels at disease progression support the hypothesis that this protease could play a role in acquired resistance by degrading IGFBP-3.

show abstract

Differential expression of IGF-binding protein-3 in normal and malignant colon and its influence on apoptosis

Cited by 27 publications

References 23 publications

Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue

Differential expression of IGF-1 mRNA isoforms in colorectal carcinoma and normal colon tissue

Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models

Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer

Contact Info

Product

Resources

About